US › Healthcare

GH Research PLC (GHRS)

US · Healthcare · Biotechnology

$29.12+3.30%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-19.0M
Profit YoY
-75.4%
EPS
$-0.31
EPS estimate
$-0.26

EPS came in at -0.31 against a street estimate of -0.26 — a miss of 19.2%.

Key statistics

Market cap
$1.93B
Forward P/E
0.0
P/B
7.31
Book value
$4.25
EPS (TTM)
$-0.91
52-week high
$31.00
52-week low
$11.32
50-day MA
$24.93
200-day MA
$17.94
Beta
1.29

Analyst view

Analysts rate GH Research PLC a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $40.00.

Shareholding

Insiders
24.23%
Institutions
69.76%

Largest institutional holders

FundStake
Lynx1 Capital Management, LP15.69%
Bvf Inc12.61%
RA Capital Management, LLC11.19%
RTW INVESTMENTS, LLC8.65%
FMR Inc7.49%
venBio Select Advisor LLC2.62%
The Toronto-Dominion Bank2.04%
Millennium Management LLC1.37%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for GH Research PLC — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.